SpyGlass Pharma, Inc., a late-stage biopharmaceutical company, has closed its initial public offering (IPO), selling a total of 10,781,250 shares of common stock. This figure includes the full exercise of the underwriters’ option to purchase an additional 1,406,250 shares. The shares were priced at $16.00 each, generating gross proceeds of $172.5 million before expenses.
The company’s common stock began trading on the Nasdaq Global Select Market under the ticker symbol “SGP” on February 6, 2026. All shares offered in the IPO were issued by SpyGlass Pharma.
**Why this matters**
The successful completion of the IPO provides SpyGlass Pharma with significant capital to support its late-stage drug development programs. Listing on Nasdaq also enhances the company’s visibility and access to public markets, which may facilitate future fundraising and strategic growth initiatives.
Source: NewsData